DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Household
Author Program NEWCreate Narrative
NAGE logo

Niagen Bioscience, Inc. Stock Price

NasdaqCM:NAGE Community·US$245.8m Market Cap
  • 3 Narratives written by author
  • 1 Comments on narratives written by author
  • 73 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

NAGE Share Price Performance

US$3.05
-6.55 (-68.23%)
​
US$12.60
Fair Value
US$3.05
-6.55 (-68.23%)
75.8% undervalued intrinsic discount
US$12.60
Fair Value
Price US$3.05
AnalystConsensusTarget US$12.60
AnalystHighTarget US$21.20
AnalystLowTarget US$9.00
Tue, 16 Jun 26
Fair ValueUS$12.60
Share Pricen/a

NAGE Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$12.6 75.8% undervalued intrinsic discount

Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects

2users have liked this narrative
1users have commented on this narrative
29users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$21.2 85.6% undervalued intrinsic discount

Expanding NAD Category And Clinical Pipeline Will Drive Powerful Long-Term Upside

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$9 66.1% undervalued intrinsic discount

NAD Market Competition And Regulatory Risks Will Challenge Margins Yet Support Long-Term Healthy Aging Demand

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
NAGE logo
Niagen Bioscience
85.6% undervalued intrinsic discount

Expanding NAD Category And Clinical Pipeline Will Drive Powerful Long-Term Upside

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 29 Jul
Read Narrative
NAGE logo
Niagen Bioscience
75.8% undervalued intrinsic discount

Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 16 Jun
Read Narrative
NAGE logo
Niagen Bioscience
66.1% undervalued intrinsic discount

NAD Market Competition And Regulatory Risks Will Challenge Margins Yet Support Long-Term Healthy Aging Demand

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 14 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
NAGE logo

NAGE: Longevity And GLP-1 Wellness Tailwinds Will Support Future Upside

Fair Value: US$21.2 85.6% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
AN
AnalystLowTarget
NAGE logo

NAGE: Rare Disease Drug Designations Will Drive Future Longevity Upside

Fair Value: US$9 66.1% undervalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
NAGE logo

NAGE: Injectables And Expanded Clinical Access Will Support Future Buyback Upside

Fair Value: US$12.6 75.8% undervalued intrinsic discount
29 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet and good value.

1 Risk
2 Rewards
View Full Analysis

Niagen Bioscience, Inc. Key Details

US$129.1m

Revenue

US$46.2m

Cost of Revenue

US$82.9m

Gross Profit

US$66.9m

Other Expenses

US$16.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.20
64.24%
12.39%
0%
View Full Analysis

About NAGE

Founded
1999
Employees
117
CEO
Robert Fried
WebsiteView website
www.niagenbioscience.com

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Recent NAGE News & Updates

Recent updates

No updates

Niagen Bioscience, Inc. Competitors

HNST logo

Honest Company

Symbol: NasdaqGS:HNST
Market cap: US$615.8m
ODD logo

Oddity Tech

Symbol: NasdaqGM:ODD
Market cap: US$600.8m
RAJA

Cordyceps Sunshine Biotech Holdings

Symbol: OTCPK:RAJA.F
Market cap: US$577.8m
HKHC logo

Horizon Kinetics Holding

Symbol: OTCPK:HKHC
Market cap: US$493.8m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide